BCR and B-cell chronic lymphocytic leukemia: Specifically, Ibrutinib, Idelalisib, and Fostamatinib enable BCR signaling, which has an essential role in the survival and proliferation of mature B lymphocytes and also affects the regulation of CLL B lymphocyte trafficking in lymphoid organs.